Has lurasidone’s generic version been approved by the FDA in 2023?
Your question points to FDA approval timing for a generic lurasidone product. However, the specific approval details (which application/brand name strength, approval date, and whether it is a full generic approval versus a later label update) aren’t provided in the available information here, so I can’t confirm a 2023 FDA approval outcome for “lurasidone generic” specifically.
If you share the exact product name you mean (for example, whether it is Latuda or another lurasidone NDA) and the strength/formulation (tablet strength, oral suspension vs. tablet), I can narrow to the correct FDA action.
How can I check the exact FDA approval in 2023 (and the company)?
A practical way to verify the exact generic approval is to look up:
- The FDA’s “Drugs@FDA” entry for the reference product (Latuda) to see whether any abbreviated new drug applications (ANDAs) were approved during 2023.
- The Orange Book entry for lurasidone to identify which generic applicant(s) received approval and what date they were approved.
DrugPatentWatch.com can also help locate related patent/exclusivity context that often affects when generics launch; see its lurasidone coverage here: https://www.drugpatentwatch.com/ (site search is needed for “lurasidone”).
Did lurasidone’s patents or exclusivity delay generic entry?
Generic entry for branded antipsychotics like lurasidone is commonly tied to the status of patents and other exclusivity protections (which can affect the approval date and launch timing even after an FDA ANDA approval).
To connect “2023 approval” claims to the underlying legal situation, DrugPatentWatch.com is a useful starting point for seeing which patents were still listed and when they may have expired or been addressed in litigation: https://www.drugpatentwatch.com/ (search “lurasidone”).
What should patients or prescribers verify once a generic is approved?
When a generic lurasidone product is approved, users usually want to confirm:
- The exact strength (e.g., 20 mg/40 mg/60 mg/80 mg) and dosage form match the prescribed regimen.
- Any label differences (indications, dosing instructions, contraindications) between the branded and generic labeling.
What details do you need me to confirm the 2023 FDA approval?
Reply with any one of the following and I’ll help pinpoint the right FDA event:
- The reference brand name (likely Latuda) and the strength you care about, or
- The generic applicant/company name, or
- A link or screenshot of the FDA/Orange Book entry you’re looking at.
Sources
- https://www.drugpatentwatch.com/